JP2018518201A5 - - Google Patents

Download PDF

Info

Publication number
JP2018518201A5
JP2018518201A5 JP2018518771A JP2018518771A JP2018518201A5 JP 2018518201 A5 JP2018518201 A5 JP 2018518201A5 JP 2018518771 A JP2018518771 A JP 2018518771A JP 2018518771 A JP2018518771 A JP 2018518771A JP 2018518201 A5 JP2018518201 A5 JP 2018518201A5
Authority
JP
Japan
Prior art keywords
sirna
amine
containing compound
pharmaceutically acceptable
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018518771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518201A (ja
JP6715325B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2016/087034 external-priority patent/WO2016206626A1/zh
Publication of JP2018518201A publication Critical patent/JP2018518201A/ja
Publication of JP2018518201A5 publication Critical patent/JP2018518201A5/ja
Application granted granted Critical
Publication of JP6715325B2 publication Critical patent/JP6715325B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018518771A 2015-06-26 2016-06-24 siRNA、siRNAを含む医薬組成物及び結合体、並びにそれらの応用 Active JP6715325B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510364229.8 2015-06-26
CN201510364229 2015-06-26
PCT/CN2016/087034 WO2016206626A1 (zh) 2015-06-26 2016-06-24 一种siRNA、含有该siRNA的药物组合物和缀合物及它们的应用

Publications (3)

Publication Number Publication Date
JP2018518201A JP2018518201A (ja) 2018-07-12
JP2018518201A5 true JP2018518201A5 (enExample) 2019-06-13
JP6715325B2 JP6715325B2 (ja) 2020-07-01

Family

ID=57584730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018518771A Active JP6715325B2 (ja) 2015-06-26 2016-06-24 siRNA、siRNAを含む医薬組成物及び結合体、並びにそれらの応用

Country Status (5)

Country Link
US (1) US20190062749A1 (enExample)
EP (1) EP3315608B1 (enExample)
JP (1) JP6715325B2 (enExample)
CN (1) CN107849567B (enExample)
WO (1) WO2016206626A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3675826T (lt) 2017-08-31 2023-09-11 Life Technologies Corporation Katijoninės lipidų kompozicijos audiniams-specifiniam įterpimui
EP3719126B1 (en) * 2017-12-01 2025-01-01 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
DK3719128T3 (da) * 2017-12-01 2025-03-03 Suzhou Ribo Life Science Co Ltd Dobbelt-strenget oligonukleotid, sammensætning og konjugat bestaende dobbelt-strenget oligonukleotid, fremgangsmåde herfor og anvendelse heraf
EP3719127A4 (en) 2017-12-01 2021-10-20 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE
CA3083970A1 (en) * 2017-12-01 2019-06-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
WO2019105404A1 (zh) * 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN110944675B9 (zh) * 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN110945131B (zh) * 2017-12-01 2024-05-28 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
AU2018394875B2 (en) 2017-12-29 2023-08-03 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
WO2020038377A1 (zh) * 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
WO2020135581A1 (zh) * 2018-12-28 2020-07-02 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2020135673A1 (zh) 2018-12-28 2020-07-02 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN111377985B (zh) * 2018-12-29 2023-11-10 苏州瑞博生物技术股份有限公司 化合物和缀合物及其制备方法和用途
CN113330117B (zh) * 2019-01-18 2024-05-28 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
AU2020280439B2 (en) 2019-05-22 2025-08-14 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
US12590304B2 (en) 2019-05-22 2026-03-31 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
CN111979237A (zh) * 2019-05-22 2020-11-24 苏州瑞博生物技术股份有限公司 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
KR20220011689A (ko) * 2019-05-22 2022-01-28 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도
CN111973617A (zh) * 2019-05-23 2020-11-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN111973618B (zh) * 2019-05-23 2024-02-02 苏州瑞博生物技术股份有限公司 核酸、药物组合物与siRNA缀合物及制备方法和用途
CN113795582B (zh) 2019-05-24 2024-05-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
US20230076803A1 (en) * 2019-08-29 2023-03-09 Suzhou Ribo Life Science Co., Ltd. Compound and drug conjugate, and preparation method and use thereof
WO2021110148A1 (zh) * 2019-12-06 2021-06-10 南京明德新药研发有限公司 siRNA缀合物、双链siRNA缀合物及其盐和应用
CN111110866B (zh) * 2019-12-30 2023-04-11 福州大学 还原性聚谷氨酸/聚乙烯亚胺/siRNA复合纳米粒及制备与应用
US20240033278A9 (en) * 2020-06-10 2024-02-01 Medshine Discovery Inc. Conjugate group and conjugate
CN113663089B (zh) * 2021-06-25 2022-10-28 北京理工大学 可电离脂质纳米颗粒组合物、制备方法及应用
WO2023116764A1 (zh) * 2021-12-23 2023-06-29 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及其用途
CN114634984A (zh) * 2022-02-02 2022-06-17 复旦大学 一种脑胶质瘤生物标记物mlkl基因及其应用
CN115487308B (zh) * 2022-09-29 2024-09-27 北京大学 反义核酸糖基缀合物及其制备方法和在肝癌治疗中的应用
JP2025542581A (ja) * 2022-12-08 2025-12-26 1グローブ ヘルス インスティテュート エルエルシー アンチセンスRNA(asRNA)技術およびその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2423060T3 (es) * 2004-03-12 2013-09-17 Alnylam Pharmaceuticals, Inc. Agentes iRNA que tienen como diana al VEGF
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2006096018A1 (en) * 2005-03-09 2006-09-14 Mogam Biotechnology Research Institute Small interfering rna and pharmaceutical composition for treatment of hepatitis b comprising the same
CN101426912A (zh) * 2005-08-17 2009-05-06 瑟纳治疗公司 介导rna干扰的化学修饰短干扰核酸分子
CN102140461B (zh) * 2010-01-29 2012-12-05 苏州瑞博生物技术有限公司 小干扰核酸和药物组合物及其制药应用
CN102140458B (zh) * 2010-01-29 2013-05-22 苏州瑞博生物技术有限公司 小干扰核酸和药物组合物及其制药应用
CN103380113B (zh) * 2010-11-15 2018-03-30 生命科技公司 含胺的转染试剂及其制备和使用方法
WO2013061295A1 (en) * 2011-10-28 2013-05-02 University Of The Witwatersrand, Johannesburg Inhibition of viral gene expression
EP3730618A1 (en) * 2011-11-18 2020-10-28 Alnylam Pharmaceuticals, Inc. Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
AU2013299717B2 (en) * 2012-08-06 2018-06-28 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugated RNA agents and process for their preparation
CA2893824A1 (en) * 2012-12-14 2014-06-19 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of ckap5 by double-stranded rna
IL288931B2 (en) * 2013-03-14 2025-05-01 Alnylam Pharmaceuticals Inc Compositions comprising a complementary portion of C5 IRNA and methods of using them

Similar Documents

Publication Publication Date Title
JP2018518201A5 (enExample)
JP6715325B2 (ja) siRNA、siRNAを含む医薬組成物及び結合体、並びにそれらの応用
JP2021533800A5 (enExample)
JP2021502120A5 (enExample)
JP2022505234A5 (enExample)
JP2014515406A5 (enExample)
IL274503B1 (en) Nucleic acids for inhibiting expression of lpa in a cell
JP2010530014A5 (enExample)
JP2019512478A5 (enExample)
JP2016520312A5 (enExample)
AU2017326372B2 (en) Modified oligonucleotides and methods of use
JP2021503940A5 (enExample)
JP2015528002A5 (enExample)
JP2014528466A5 (enExample)
JP2014528467A5 (enExample)
JP2018520685A5 (enExample)
JP2008538381A5 (enExample)
JP2016529230A5 (enExample)
JP2010505741A5 (enExample)
JP2011528654A5 (enExample)
JP2004537517A5 (enExample)
JP2010527913A5 (enExample)
JP2010526917A5 (enExample)
FI3550023T3 (fi) Oligomeerejä ja oligomeerikonjugaatteja
JP2022534069A5 (enExample)